Par'Immune
Marquette Lez Lille · Founded 2017
About Par'Immune
Par'Immune develops P28GST, a parasite-derived protein used as an immunotherapy to treat autoimmune conditions like Crohn's disease.
Company Facts
- Founded: 2017
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 251 – 500
- Estimated revenue: Less than $1M
- Last round: Non-Equity Assistance (Apr 2018)
- Website: http://www.parimmune.com/
- Phone: +33 67 778 41 83
Social Profiles
Canonical: https://fsome.com/organization/par-immune-1823268 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.